The agency said benefits of Leqembi in slowing down progression of disease symptoms are greater than its risks in patients with one or no copy of the gene variant, which was assessed during the re-examination The agency said benefits of Leqembi in slowing down progression of disease symptoms are greater than its risks in patients with one or no copy of the gene variant, which was assessed during the re-examination World Health News, Wellbeing Tips, Diseases, Treatment and Nutrition | The Hindu
EU regulator backs Eisai-Biogen Alzheimer’s drug
